Every year the number of patients who suffer from musculoskeletal diseases, especially bone cancer, is rapidly increasing. Long-term treatment is needed, which typically involves a multidisciplinary approach, including a combination of surgical procedures and drug chemotherapy. This often negatively affects the health of patients, causing side effects such as neurological disorders and heart diseases as well as the development of drug resistance [1]. Furthermore, after tumour resection a large void remains at the affected bone site that preferably must be filled with an appropriate biomaterial, such as calcium phosphate bone cements (CPCs), due to their ability to induce bone tissue regeneration and, also, to serve as local drug delivery systems. Thus, the aim of this study was to evaluate the influence of the drug addition and the variation of different solid and liquid phase compositions on the physico-chemical properties of prepared CPCs, as well as on the drug release kinetics. CPCs were prepared by using α-tricalcium phosphate (α-TCP) as a solid phase (synthesized at different temperatures) and 0.5 M and 1 M sodium salt solutions as the liquid phase. Doxorubicin (DOX) was used as an anticancer agent and its amount loaded in CPCs was estimated as 1.5wt% from the solid phase. Obtained cements were characterized using XRD, BET, SEM, Archimedes method and helium pycnometry. The setting time of the prepared CPCs was measured by Vicat needle. The release kinetics of the DOX were analyzed by UV-VIS at λ=480nm. The experimental results indicated that addition of DOX affects the setting time and porosity of CPCs, but does not influence the bone cement density. Moreover, setting time of CPCs was affected by both changes in liquid phase molarity and α-TCP synthesis temperature. It was found that the synthesis temperature of the solid phase also affects the composition of the crystalline phase of developed calcium phosphate bone cements. Obtained results revealed that the release of DOX from the CPCs can be controlled not only by varying the solid phase synthesis temperature, but also by changing the molarity of the liquid phase. Therefore, studies showed that DOX-loaded CPCs are able to gradually release the active substance for more than 60 days. According to the results, DOX loaded CPCs have a potential to be used as porous injectable biomaterials for bone tissue regeneration and drug delivery, however further studies are required in order to establish their efficiency for bone cancer treatment. Acknowledgements The authors acknowledge financial support from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No. 857287 (BBCE – Baltic Biomaterials Centre of Excellence) and the Ministry of Economics Republic of Latvia project "State research project in the field of biomedicine, medical technologies and pharmacy", project No. VPP-EM-BIOMEDICĪNA-2022/1-0001 (BioMedPharm). References 1. Wang, S.-Y.; Hu, H. Z.; Qing, X.; Zhang, Z. C.; Shao, Z. W. Recent Advances of Drug Delivery Nanocarriers in Osteosarcoma Treatment. J. Cancer 2020, 11 (1), 69-82. https://doi.org/10.7150/jca.36588.